Serina Therapeutics shares rise 11.59% intraday after CEO discusses FDA policy impacts and FDA approves SER-252 IND application for late-stage Parkinson's.

Serina Therapeutics surged 11.59% intraday, as the company’s CEO participated in a webinar discussing FDA policies impacting drug development timelines and the FDA approved its IND application for SER-252, enabling Phase 1b trials for late-stage Parkinson’s disease. The company focuses on developing its proprietary POZ technology platform to treat neurological diseases and pain, with core products including SER-252 for Parkinson’s disease and SER-227 for long-term pain relief.